Shire’s NPS Purchase Highlights Its Orphan Drug Strategy Post-AbbVie Bid
Executive Summary
The Dublin-based drugmaker’s buy of rare disease specialist NPS Pharma signals it is back on the offensive after AbbVie’s aborted bid, but observers say the deal’s sound logic may make Shire a takeover target again.
You may also be interested in...
Patient-Centric: Evotec’s CSO Explains R&D Strategy
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk, Evotec Link Around Chronic Kidney Disease
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: